TRICIDA INC's ticker is TCDA and the CUSIP is 89610F101. A total of 104 filers reported holding TRICIDA INC in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $726,000 | +17.7% | 75,000 | 0.0% | 0.01% | +14.3% |
| Q1 2022 | $617,000 | -13.9% | 75,000 | 0.0% | 0.01% | -12.5% |
| Q4 2021 | $717,000 | +106.0% | 75,000 | 0.0% | 0.01% | +100.0% |
| Q3 2021 | $348,000 | +7.4% | 75,000 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $324,000 | -45.6% | 75,000 | -33.5% | 0.00% | -50.0% |
| Q1 2021 | $596,000 | -70.9% | 112,725 | -50.2% | 0.01% | -74.2% |
| Q3 2020 | $2,049,000 | -62.7% | 226,188 | +13.2% | 0.03% | -62.7% |
| Q2 2020 | $5,493,000 | +71.3% | 199,888 | +37.1% | 0.08% | +29.7% |
| Q1 2020 | $3,207,000 | -21.1% | 145,788 | +35.3% | 0.06% | +18.5% |
| Q4 2019 | $4,066,000 | +29.8% | 107,729 | +6.2% | 0.05% | +20.0% |
| Q3 2019 | $3,132,000 | +6.9% | 101,443 | +36.6% | 0.04% | +18.4% |
| Q2 2019 | $2,931,000 | +205.0% | 74,275 | +198.6% | 0.04% | +192.3% |
| Q1 2019 | $961,000 | +62.9% | 24,876 | -0.5% | 0.01% | +44.4% |
| Q4 2018 | $590,000 | -22.8% | 25,000 | 0.0% | 0.01% | +12.5% |
| Q3 2018 | $764,000 | +2.1% | 25,000 | 0.0% | 0.01% | +14.3% |
| Q2 2018 | $748,000 | – | 25,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 9,614,280 | $362,843,000 | 5.18% |
| Redmile Group, LLC | 2,129,100 | $80,352,000 | 1.92% |
| Burrage Capital Management LLC | 70,653 | $2,666,000 | 1.79% |
| Avoro Capital Advisors LLC | 1,560,000 | $58,874,000 | 1.73% |
| Opaleye Management Inc. | 194,000 | $7,303,000 | 1.43% |
| Cormorant Asset Management, LP | 927,975 | $35,022,000 | 1.40% |
| Duquesne Family Office | 688,344 | $25,978,000 | 0.76% |
| H2O AM LLP | 67,991 | $2,566,000 | 0.61% |
| Artal Group S.A. | 360,000 | $13,586,000 | 0.52% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 37,000 | $1,393,000 | 0.50% |